These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 17251496

  • 21. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M, Kawasaki M, Nishigaki K, Takemura G, Fujiwara H.
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [Abstract] [Full Text] [Related]

  • 22. [The experimental study of captopril and valsartan on the preventing and treatment of diabetic retinopathy in diabetic mice].
    Xie XW, Zhao P.
    Zhonghua Yan Ke Za Zhi; 2004 Nov; 40(11):770-3. PubMed ID: 15634486
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. A role for omega-3 polyunsaturated fatty acid supplements in diabetic neuropathy.
    Yee P, Weymouth AE, Fletcher EL, Vingrys AJ.
    Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1755-64. PubMed ID: 19907026
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.
    Tominaga N, Robert A, Izuhara Y, Ohtomo S, Dan T, Chihara K, Kurokawa K, Van Ypersele de Strihou C, Miyata T.
    Nephrology (Carlton); 2009 Sep; 14(6):581-7. PubMed ID: 19712258
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat.
    Wilkinson-Berka JL, Gibbs NJ, Cooper ME, Skinner SL, Kelly DJ.
    Nephrol Dial Transplant; 2001 Jul; 16(7):1343-9. PubMed ID: 11427623
    [Abstract] [Full Text] [Related]

  • 31. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.
    Kelly DJ, Cox AJ, Tolcos M, Cooper ME, Wilkinson-Berka JL, Gilbert RE.
    Kidney Int; 2002 Jan; 61(1):31-9. PubMed ID: 11786082
    [Abstract] [Full Text] [Related]

  • 32. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
    Flammer AJ, Hermann F, Wiesli P, Schwegler B, Chenevard R, Hürlimann D, Sudano I, Gay S, Neidhart M, Riesen W, Ruschitzka F, Lüscher TF, Noll G, Lehmann R.
    J Hypertens; 2007 Apr; 25(4):785-91. PubMed ID: 17351370
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The renin-angiotensin system and the developing retinal vasculature.
    Sarlos S, Wilkinson-Berka JL.
    Invest Ophthalmol Vis Sci; 2005 Mar; 46(3):1069-77. PubMed ID: 15728567
    [Abstract] [Full Text] [Related]

  • 38. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
    Katayama S, Yagi S, Yamamoto H, Yamaguchi M, Izumida T, Noguchi Y, Inaba M, Inukai K.
    Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
    [Abstract] [Full Text] [Related]

  • 39. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
    Yarows SA, Oparil S, Patel S, Fang H, Zhang J.
    Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
    [Abstract] [Full Text] [Related]

  • 40. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.